ERBB2 and cancer: In women with luminal B (HER2–) cancer, univariate analyses showed that for DDFS, Tstage and node status were significant unfavorable prognostic factors and PR was a significantfavorable prognostic factor, while for OS, T stage and node status were significant unfavorableprognostic factors and PR and hormone therapy were significant favorable prognostic factors.